Verrica Pharmaceuticals made $5.7 million from YCANTH sales last quarter, up 11.9% from the last quarter.

Nov 12, 2026, 4:29 PM ETResultsRead the original at SEC EDGAR

Good for VRCA

Verrica reported rising YCANTH sales and gained access to $27.5 million in growth funding, enough to operate through both common-wart trial results. The results are still pending and VP-315 work for Gorlin syndrome remains exploratory, but sales growth and funding make this update favorable.

VRCA · Verrica Pharmaceuticals Inc.

AI read · Good for VRCA

The AI's read

Funding can carry Verrica through results from both common-wart trials, and growing YCANTH sales give it a stronger commercial base. Neither trial has reported results, and VP-315 for Gorlin syndrome is only being explored. Current sales growth and available funding make the update favorable despite those unanswered questions.

Get alerts for VRCA

Follow Verrica Pharmaceuticals Inc. (VRCA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VRCA

Free on the App Store and Google Play, or on the web.